CXCL10 Promotes Invasion-Related Properties in Human Colorectal Carcinoma Cells
- 1 April 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (7), 3396-3405
- https://doi.org/10.1158/0008-5472.can-06-3087
Abstract
CXCL10 was recently shown to exert antimalignancy functions by influencing the tumor microenvironment. Here, we have taken a different approach, investigating the effects of CXCL10 directly on tumor-promoting functions in colorectal carcinoma (CRC) cells. CXCL10 expression was detected in preferred metastatic sites of CRC (liver, lungs, and lymph nodes), and its CXCR3 receptor was expressed by eight CRC cell lines (detected: reverse transcription-PCR and/or flow cytometry). Detailed analysis was done on two cell lines derived from primary CRC tumors (SW480, KM12C) and their metastatic descendents (SW620 and KM12SM). The three known variants of CXCR3 (CXCR3-A, CXCR3-B, and CXCR3-alt) were detected in all four cell lines. CXCR3 expression was also observed on colorectal tumor cells in biopsies of CRC patients (immunohistochemistry). CXCL10 and CXCR3 expression were potently induced in CRC cells by Interferon γ and all four CRC cell lines responded to CXCL10 by extracellular signal-regulated kinase 1/2 dephosphorylation. The chemokine did not affect tumor cell growth or angiogenesis-related functions in the tumor cells, such as CXCL8 and vascular endothelial growth factor secretion. Importantly, CXCL10 significantly up-regulated invasion-related properties in CRC cells: It promoted matrix metalloproteinase 9 expression and induced CRC cell migration. Of note, CXCL10-induced migration was detected only in the two metastatic cells and not in their primary counterparts. Also, CXCL10 promoted the adhesion of metastatic cells to laminin. These results suggest that CXCL10 can be exploited by CRC cells toward their progression, thus possibly antagonizing the antimalignancy effects of the chemokine on the tumor microenvironment. Therefore, care should be taken when considering CXCL10 as a therapeutic antitumor modality for CRC treatment. [Cancer Res 2007;67(7):3396–405]Keywords
This publication has 47 references indexed in Scilit:
- The multifaceted roles of chemokines in malignancyCancer and Metastasis Reviews, 2006
- Cancer CXC chemokine networks and tumour angiogenesisEuropean Journal Of Cancer, 2006
- Improved Therapeutic Effectiveness by Combining Recombinant CXC Chemokine Ligand 10 with Cisplatin in Solid TumorsClinical Cancer Research, 2005
- Cancer and the chemokine networkNature Reviews Cancer, 2004
- Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysisLaboratory Investigation, 2004
- Tumour-cell invasion and migration: diversity and escape mechanismsNature Reviews Cancer, 2003
- Dissemination and growth of cancer cells in metastatic sitesNature Reviews Cancer, 2002
- CXC Chemokine Expression After Stimulation with Interferon-?? in Primary Rat Hepatocytes in CultureShock, 2002
- Enhanced Expression of Interferon-Regulated Genes in the Liver of Patients with Chronic Hepatitis C Virus Infection: Detection by Suppression-Subtractive HybridizationJournal of Virology, 2001
- Differential expression and regulation of chemokines JE, KC, and IP-10 gene in primary cultured murine hepatocytesJournal of Cellular Physiology, 1999